INVESTORS & ADVISORS
James O. McCash, Investor, is a former owner and executive, of a national contracting firm and has been committed to the research and development of new therapies for the treatment of various types of cancer.
Cheryl A. London, DVM, Ph.D., is the current Director of the Clinical Trials Office at the Cummings School of Veterinary Medicine at Tufts University. She is a veterinary medical oncologist with over 20 years of experience in the fields of translational and comparative oncology and drug development.
Jinhui Dou, Ph.D. After receiving his BS (Pharmacy) and MS (Pharmacognosy) degrees, Jinhui Dou became a faculty member at Beijing University of Chinese Medicine and taught pharmacy classes for 4 years.
He accepted a graduate assistantship from the Pharmacognosy Department at the University of Mississippi and received a PhD degree in 1996 from Dr. James McChesney, a distinguished professor of pharmacognosy. After working at the University of Kansas as a post-doc associate, he became a Natural Product Scientist at NaPro BioTherapeutics in December 1996. He led a group of chemists and engineers in the reduction of paclitaxel manufacturing costs and in the establishment of a library of related-substance reference standards to support the CMC, pharmacology, and toxicology sections of paclitaxel NDA and ANDA filings.
Dr. Dou joined the FDA in 2002 as a pharmacologist reviewer in the Center for Drug Evaluation and Research (CDER). He reviewed anti-infective and anti-inflammatory chemical-drug filings for several years before working as a botanical reviewer full time. He was a CDER and Agency expert pharmacologist and pharmacognosist specialized in botanical drug review. Dr. Dou received numerous awards from CDER, FDA, and HHS for his distinguished contributions to the development of new guidances, policies, and regulations and his scientific reviews of new botanical and chemical drugs.
After more than 15 years at FDA, Dr. Dou, in 2017, joined Yiling Pharmaceutical, headquartered in Shijiazhuang, China, as a Vice Dean of the Yiling Research Institute. He now works as a pharmacology and pharmacognosy consultant for the pharmaceutical industry worldwide.
Dr. Dou is a member of American Society of Pharmacognosy (ASP) and the NIH/NCI PDQ Integrative, Alternative, and Complementary Therapies (IACT) editorial board. His publications on lupin alkaloids, green tea, quassinoinds, and proanthocyanidins are from his research activities or new drug review experience.